One other promising pharmaceutical agent is the BRAF inhibitor vemurafenib, which recently exhibited dramatic efficacy in the treatment of three ECD patients whose histiocytes were positive for the V600E BRAF mutation [101]. This evidence concerns the gene BRAF and familial atrioventricular septal defect.